(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy - 2Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- 3Seoul says sorry after unapproved drone flights into North Korea
- 45 Arising Professions in Environmentally friendly power
- 5Geomagnetic storm grounds launch of Mars space weather satellites
- Strengthening through Wellness: Individual Preparation Achievement
- Los Angeles County sees significant uptick in norovirus cases, officials say
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- How to watch the last supermoon of the year
- Dominating the Art of Composing: Creator Bits of knowledge
- Iran War Derails The Automotive Industry
- Figure out How to Reveal Stowed away Open Record Rewards
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress
